Dual Diagnosis

Biography

Dr. Weiss’ career has focused on treatment and clinical research with substance-dependent patients. He has received numerous NIH grants, developing integrated group therapy, an evidence-based treatment for co-occurring bipolar and substance use disorders, and leading a multi-site treatment study of prescription opioid dependence. He has authored over 300 publications, including several books, and was vice chair of the American Psychiatric Association Task Force on Practice Guidelines for Patients with Substance Use Disorders. Dr. Weiss was named a member of honor by the Spanish Society for Dual Disorders in 2011, and has received numerous other awards, including the H. David Archibald Award for Outstanding Research and/or Practice in the Addictions from The Centre for Addiction and Mental Health in Toronto (2007), the Jack H. Mendelson Research Award from McLean Hospital (2012), and the Dan Anderson Research Award from the Hazelden Foundation (2012).

Research Interest

Our Scientific Panel of Advisors was extremely impressed with the scientific rigor of this study, its two phase methodology, and the fact it examined extended buprenorphine maintenance," stated Dr. Audrey Klein, director of the Butler Center for Research at the Hazelden Foundation. "His current work on the use of long term buprenorphine is innovative, timely, and essential given the current epidemic of prescription opioid addiction and increase in deaths related to opioid overdose.